^
    11ms
    SWOG-S1221: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (clinicaltrials.gov)
    P1/2, N=27, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF mutation • BRAF V600 • RAS mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • uprosertib (LAE003)
    1year
    SWOG-S1221: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date • Combination therapy
    |
    BRAF mutation • BRAF V600 • RAS mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • uprosertib (LAE003)
    2years
    SWOG-S1221: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2024
    Trial completion date • Combination therapy
    |
    BRAF mutation • BRAF V600 • RAS mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • uprosertib (LAE003)
    over2years
    Comprehensive analysis of angiogenesis pattern and related immune landscape for individual treatment in osteosarcoma. (PubMed, NPJ Precis Oncol)
    OS patients with high ANGscore might be resistant to uprosertib, and be sensitive to VE821, AZD6738 and BMS.345541. In conclusion, we established a novel ANGscore system by comprehensively analysing the expression pattern of angiogenesis genes, which can accurately differentiate the prognosis and immune characteristics of OS populations. Additionally, the ANGscore can be used for patient stratification during immunotherapy, and guide individualized treatment strategies.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    ceralasertib (AZD6738) • VE-821 • uprosertib (LAE003)
    almost4years
    Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=25, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene)
    |
    Mekinist (trametinib) • uprosertib (LAE003)
    over4years
    RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer. (PubMed, J Cancer)
    Our data demonstrated that RNF43 and PWWP2B are a biomarker that predict recurrence of gastric cancer. Our findings suggest that docetaxel trihydrate, uprosertib and pelitinib could be used as novel therapeutic agents for the prevention and treatment of gastric cancer with a decrease in RNF43 and PWWP2B expression.
    Clinical • FDA event • Journal
    |
    RNF43 (Ring Finger Protein 43)
    |
    docetaxel • uprosertib (LAE003)
    5years
    Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. (PubMed, Cancer Chemother Pharmacol)
    Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested.
    Clinical • P1 data • Journal • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • MAP2K2 (Mitogen-activated protein kinase kinase 2)
    |
    Mekinist (trametinib) • uprosertib (LAE003)
    5years
    Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov)
    P1, N=26, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Clinical • Trial completion • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mekinist (trametinib) • uprosertib (LAE003)
    5years
    Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, National Cancer Institute (NCI) | N=74 --> 25
    Clinical • Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    Mekinist (trametinib) • uprosertib (LAE003)